MDGL

Madrigal Pharmaceuticals Inc. (MDGL) | Rumor.io

Madrigal Pharmaceuticals

MDGL

Attention (50-day avg)0%

Attention rank (50-day avg)#902

Bullish sentiment (50-day avg)94%

Price to earnings ratio-40.3

Market capitalization11.9B

Earnings per share-14

Dividend yield (TTM)—

Revenue (annual)958.4M

Net income (annual)-288.3M

Social

What share of all stock conversation is about MDGL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.02	0.01% +0	0% +0	0% -0.01

Aug 26

Madrigal Pharmaceuticals' stock has been a winner with Rezdiffra, and some investors are expecting it to rocket higher.
The company's stock trades with light volumes and thin options volumes, which may affect investor confidence.
There are rumors of a potential buyout, with some investors speculating about a possible acquisition by Novartis or another large stakeholder.

Generated by AI

Sentiment

Of the messages about MDGL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	85.71% -14.29	93.59% +0.57	91.5% -1.34	84.54% -3.15
Bearish	14.29% +14.29	6.41% -0.57	8.5% +1.34	15.46% +3.15

Bullish· Jul 30

The company has generated $1.3 billion in revenue from its lead drug in just over a year, with a potential market size of $15-35 billion.
The drug has a strong market with over 50,000 patients on therapy, and the company is poised to capture a significant share of the market with its effective treatment.
The company's revenue run rate is almost at $1.5 billion, barely into its third year of launch, and the active patient base has surged past 49,000, confirming robust market demand despite new competition.

Bearish· May 6

Madrigal Pharmaceuticals' management has made questionable decisions, such as a large share buyback at higher prices, which may be reminiscent of a poorly managed company.
The company's revenue and EPS have declined, with revenue growth slowing and price pressure/discount concerns arising from the decline in revenue per patient.
The company's top-line growth has been disappointing, with new patient growth slower than expected, and the potential for a buyout or acquisition may not be as clear-cut as some investors believe.

Generated by AI

Topics

Of the messages about MDGL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	71.5%	86.25%	75.68%
Analysts	—	28.5%	13.75%	12.12%
Technical Analysis	—	0%	0%	7.47%
Earnings	—	0%	0%	3.53%
Controversies	—	0%	0%	0.55%
Macro	—	0%	0%	0.64%

Earnings· Feb 26

Madrigal Pharmaceuticals' Q4 2024 earnings report shows a net loss of $59.42M, with EPS of $(2.71) beating expectations of $(4.11) and revenue of $103.3M beating expectations of $97.81M.
The company's cash position remains robust at $931.3M, and 11,800+ patients are on Rezdiffra by year-end, with a significant opportunity in the F4C patient population.
Two-year data from a late-stage study evaluating Rezdiffra shows benefits in MASH cirrhosis patients, with the company aiming for strong performance in 2025 and beyond.

Analysts· Mar 15

Analysts have raised price targets for $MDGL to $425 at HCW, $397 at JMP, and $389 at Citi.
Multiple analysts have updated price targets for $MDGL following the FDA approval of Resmetirom, with estimates ranging from $3.4B to $6.4B in peak sales.
Analysts have upgraded their ratings for $MDGL, with B. Riley raising its price target to $270 and upgrading to Neutral from Sell, and other analysts maintaining Buy ratings with raised price targets.

Announcements· Mar 27

Madrigal Pharmaceuticals ($MDGL) is being considered for a buyout, potentially becoming a "golden goose" through partnerships of its NASH asset.
The company's Rezdiffra drug has been approved by the US FDA for treating MASH with moderate to advanced fibrosis.
Madrigal's EU sales have not yet started due to the MFN policy, representing untapped virgin revenues, making it an attractive target for companies like Eli Lilly ($LLY).

Technical Analysis· Dec 22

$MDGL is forming a rising wedge with decreasing volume, suggesting a potential drop.
The RSI is showing a negative divergence on every time frame, indicating a possible reversal.
A support level of $250 is mentioned, below which the stock could drop to $70.

Generated by AI

Community

Of the messages about MDGL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	44.44%	95.3%	92.59%	83.65%
Newcomers	55.56%	4.7%	7.41%	16.35%

Regulars· Aug 26

Madrigal Pharmaceuticals has seen a good bounce, with some speculating about potential interest from Novartis.
Trading volumes for Madrigal stock are very light, with options volumes also being thin, raising concerns about market sentiment.
Madrigal's stock price has been influenced by a large investment from an unknown entity and a significant increase in stake by Paulson, potentially setting the stage for a price increase.

Newcomers· Jul 6

Newcomers are weighing whether the current price of $528.10 is a breakout or a trap, with some considering it a swing trade opportunity.
Many are focused on the potential for a pullback, with some wondering how far the stock can run before a retracement, and others discussing price targets.
Some newcomers are trying to decide whether to hold for biotech headlines or to take profits now, with some considering the stock an earnings/clinical news play or a pure momentum play.

Generated by AI

News

Goldman Sachs assumes Madrigal Pharmaceuticals stock with buy rating

6d agoInvesting.com

Madrigal at cantor healthcare conference: growth, access and pipeline

19d agoInvesting.com

Here's Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take Off | The Motley Fool

Rezdiffra's biggest growth opportunity may still be ahead.

1mo agoThe Motley Fool

Also Discussed

Investors talking about MDGL also mention

#	Name	Attention
1	Viking Therapeutics, Inc.VKTX	0.18%0
2	ETNB - 89bio, Inc.	——
3	GNFT - Genfit S.A.	——
4	MTSR - Metsera, Inc.	——
5	Structure Therapeutics Inc. American Depositary SharesGPCR	0%new
6	VRNA - Verona Pharma plc	——
7	Inventiva S.A. American Depositary ReceiptIVA	0%-0.01
8	TERN - Terns Pharmaceuticals, Inc.	——
9	Iovance Biotherapeutics Inc.IOVA	1.03%+0.91
10	TG Therapeutics Inc.TGTX	0.01%+0

Madrigal Pharmaceuticals Inc.

Healthcare
Biotechnology

Madrigal Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with significant unmet medical need. Its lead product, Rezdiffra, is a once-daily oral therapy designed to address the underlying biology of MASH in adults with moderate to advanced liver fibrosis. The company’s current business is centered on liver disease, with a commercial presence supported by medical affairs, patient support, and market access activities. Madrigal Pharmaceuticals Inc. also maintains research and clinical development efforts around thyroid hormone receptor-beta science, reinforcing its role as a specialist company in hepatology and metabolic medicine. Based in West Conshohocken, Pennsylvania, Madrigal Pharmaceuticals Inc. serves a focused segment of the biopharmaceutical market that targets chronic liver and metabolic disorders.

Website

Location

1001 Conshohocken State Road

West Conshohocken, PA, 19428

United States

Social

What share of all stock conversation is about MDGL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.02	0.01% +0	0% +0	0% -0.01

Aug 26

Madrigal Pharmaceuticals' stock has been a winner with Rezdiffra, and some investors are expecting it to rocket higher.
The company's stock trades with light volumes and thin options volumes, which may affect investor confidence.
There are rumors of a potential buyout, with some investors speculating about a possible acquisition by Novartis or another large stakeholder.

Generated by AI

Sentiment

Of the messages about MDGL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	85.71% -14.29	93.59% +0.57	91.5% -1.34	84.54% -3.15
Bearish	14.29% +14.29	6.41% -0.57	8.5% +1.34	15.46% +3.15

Bullish· Jul 30

The company has generated $1.3 billion in revenue from its lead drug in just over a year, with a potential market size of $15-35 billion.
The drug has a strong market with over 50,000 patients on therapy, and the company is poised to capture a significant share of the market with its effective treatment.
The company's revenue run rate is almost at $1.5 billion, barely into its third year of launch, and the active patient base has surged past 49,000, confirming robust market demand despite new competition.

Bearish· May 6

Madrigal Pharmaceuticals' management has made questionable decisions, such as a large share buyback at higher prices, which may be reminiscent of a poorly managed company.
The company's revenue and EPS have declined, with revenue growth slowing and price pressure/discount concerns arising from the decline in revenue per patient.
The company's top-line growth has been disappointing, with new patient growth slower than expected, and the potential for a buyout or acquisition may not be as clear-cut as some investors believe.

Generated by AI

Topics

Of the messages about MDGL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	71.5%	86.25%	75.68%
Analysts	—	28.5%	13.75%	12.12%
Technical Analysis	—	0%	0%	7.47%
Earnings	—	0%	0%	3.53%
Controversies	—	0%	0%	0.55%
Macro	—	0%	0%	0.64%

Earnings· Feb 26

Madrigal Pharmaceuticals' Q4 2024 earnings report shows a net loss of $59.42M, with EPS of $(2.71) beating expectations of $(4.11) and revenue of $103.3M beating expectations of $97.81M.
The company's cash position remains robust at $931.3M, and 11,800+ patients are on Rezdiffra by year-end, with a significant opportunity in the F4C patient population.
Two-year data from a late-stage study evaluating Rezdiffra shows benefits in MASH cirrhosis patients, with the company aiming for strong performance in 2025 and beyond.

Analysts· Mar 15

Analysts have raised price targets for $MDGL to $425 at HCW, $397 at JMP, and $389 at Citi.
Multiple analysts have updated price targets for $MDGL following the FDA approval of Resmetirom, with estimates ranging from $3.4B to $6.4B in peak sales.
Analysts have upgraded their ratings for $MDGL, with B. Riley raising its price target to $270 and upgrading to Neutral from Sell, and other analysts maintaining Buy ratings with raised price targets.

Announcements· Mar 27

Madrigal Pharmaceuticals ($MDGL) is being considered for a buyout, potentially becoming a "golden goose" through partnerships of its NASH asset.
The company's Rezdiffra drug has been approved by the US FDA for treating MASH with moderate to advanced fibrosis.
Madrigal's EU sales have not yet started due to the MFN policy, representing untapped virgin revenues, making it an attractive target for companies like Eli Lilly ($LLY).

Technical Analysis· Dec 22

$MDGL is forming a rising wedge with decreasing volume, suggesting a potential drop.
The RSI is showing a negative divergence on every time frame, indicating a possible reversal.
A support level of $250 is mentioned, below which the stock could drop to $70.

Generated by AI

Community

Of the messages about MDGL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	44.44%	95.3%	92.59%	83.65%
Newcomers	55.56%	4.7%	7.41%	16.35%

Regulars· Aug 26

Madrigal Pharmaceuticals has seen a good bounce, with some speculating about potential interest from Novartis.
Trading volumes for Madrigal stock are very light, with options volumes also being thin, raising concerns about market sentiment.
Madrigal's stock price has been influenced by a large investment from an unknown entity and a significant increase in stake by Paulson, potentially setting the stage for a price increase.

Newcomers· Jul 6

Newcomers are weighing whether the current price of $528.10 is a breakout or a trap, with some considering it a swing trade opportunity.
Many are focused on the potential for a pullback, with some wondering how far the stock can run before a retracement, and others discussing price targets.
Some newcomers are trying to decide whether to hold for biotech headlines or to take profits now, with some considering the stock an earnings/clinical news play or a pure momentum play.

Generated by AI

Madrigal Pharmaceuticals

Social

Aug 26

Bullish· Jul 30

Bearish· May 6

Earnings· Feb 26

Analysts· Mar 15

Announcements· Mar 27

Technical Analysis· Dec 22

Regulars· Aug 26

Newcomers· Jul 6

Goldman Sachs assumes Madrigal Pharmaceuticals stock with buy rating

Madrigal at cantor healthcare conference: growth, access and pipeline

Here's Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take Off | The Motley Fool

Madrigal Pharmaceuticals appoints J&J executive to board

Madrigal at Canaccord Genuity growth conference: Rezdiffra gains pace

Wolfe Research upgrades Madrigal Pharmaceuticals stock rating on Q2 beat

Also Discussed

Madrigal Pharmaceuticals Inc.

Company Information

Location

Goldman Sachs assumes Madrigal Pharmaceuticals stock with buy rating

Madrigal at cantor healthcare conference: growth, access and pipeline

Here's Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take Off | The Motley Fool

Madrigal Pharmaceuticals appoints J&J executive to board

Madrigal at Canaccord Genuity growth conference: Rezdiffra gains pace

Wolfe Research upgrades Madrigal Pharmaceuticals stock rating on Q2 beat

Also Discussed

Social

Aug 26

Bullish· Jul 30

Bearish· May 6

Earnings· Feb 26

Analysts· Mar 15

Announcements· Mar 27

Technical Analysis· Dec 22

Regulars· Aug 26

Newcomers· Jul 6